STOCK TITAN

Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, has announced it will host a live conference call and audio webcast on August 13, 2024, at 8:30 a.m. ET. The purpose of this event is to report financial results for the second quarter ended June 30, 2024, and provide a business overview.

Interested parties can access the call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and referring to conference ID 5436125. A live audio webcast will be available on the Investors' section of Chimerix's website, with an archived version accessible approximately two hours after the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-1.53% News Effect

On the day this news was published, CMRX declined 1.53%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview.

To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com


FAQ

When will Chimerix (CMRX) report its Q2 2024 financial results?

Chimerix (CMRX) will report its Q2 2024 financial results on Tuesday, August 13, 2024, during a live conference call and audio webcast at 8:30 a.m. ET.

How can investors access Chimerix's (CMRX) Q2 2024 earnings call?

Investors can access Chimerix's (CMRX) Q2 2024 earnings call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and using conference ID 5436125. A live audio webcast will also be available on the company's website.

What period will Chimerix's (CMRX) Q2 2024 financial results cover?

Chimerix's (CMRX) Q2 2024 financial results will cover the second quarter ended June 30, 2024.

Where can I find the archived webcast of Chimerix's (CMRX) Q2 2024 earnings call?

The archived webcast of Chimerix's (CMRX) Q2 2024 earnings call will be available on the Chimerix website approximately two hours after the live event.
Chimerix

NASDAQ:CMRX

CMRX Rankings

CMRX Latest News

CMRX Latest SEC Filings

CMRX Stock Data

354.50M
91.95M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
DURHAM